Sterling Pharma Solutions launches following management buyout
Sterling Pharma Solutions’ site in Dudley, UK.
The CDMO will specialise in delivering API development and manufacturing solutions.
UK-based Sterling Pharma Solutions has formed as an independent contract development and manufacturing organisation (CDMO) following a management buyout (MBO) of the UK-based Dudley site.
Formerly operating as Shasun Pharma Solutions within Strides Shasun, the process of divesting the business to the current management team was completed in September 2016.
Following the MBO, the newly divested business has been rebranded and launched as Sterling Pharma Solutions. The CDMO will specialise in delivering API development and manufacturing solutions to support global pharmaceutical companies across the entire product lifecycle.
The management team will be led by Kevin Cook as CEO. Kevin joined the Dudley site in 1993. He says: “We are delighted to complete the MBO and excited about building a global API services business with roots in the north east of England. Our offering is compelling as we can take projects from proof of concept to commercial scale manufacture all on one site. We also have the capabilities to handle the most hazardous chemical processes safely.
“We have experienced significant growth in the US and Europe in recent years and believe the extensive capabilities at our site, coupled with our heritage in the API services sector, provide us with an excellent foundation to become the leading partner and provider of API services to the pharmaceutical industry.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.